| Literature DB >> 35265150 |
Rajib Das1, Mashia Subha Lami1, Arka Jyoti Chakraborty1, Saikat Mitra1, Trina Ekawati Tallei2,3, Rinaldi Idroes4, Amany Abdel-Rahman Mohamed5, Md Jamal Hossain6, Kuldeep Dhama7, Gomaa Mostafa-Hedeab8, Talha Bin Emran9.
Abstract
Ginkgo biloba is an ancient plant species that is thought to provide a variety of health benefits to living organisms and contains plenty of bioactive components, making it a chemically diversified plant. G. biloba has been shown to have a variety of medicinal and pharmacological properties, including anticancer, antidementia, antidiabetic, antiobesity, antilipidemic, antimicrobial, antioxidant, antilipid peroxidation, antiplatelet, anti-inflammatory, hepatoprotective, antidepressant, antiaging, immunomodulatory, antihypertensive, and neuroprotective effects and is frequently used to treat neurological, cardiovascular, and respiratory diseases, such as tardive dyskinesia. Therefore, this review described the therapeutic applications of G. biloba. In addition to describing the therapeutic potential, this review also evaluates the chemical constituents, toxicity, adverse effect, synergistic effect, and the clinical studies of this plant which have been utilized for therapeutic benefits but have demonstrated other consequences. The capacity of G. biloba components to act as free radical scavengers is critical, and combining its extract with other plant extracts has been shown to synergistically boost antioxidant properties. G. biloba used long-term or at high doses that resulted in some adverse effects. Severe drug interactions have also been reported in both animals and humans when combined with other medications. The available data established from both preclinical and clinical studies confirm the potential of G. biloba plant extract in various diseases. Besides, the safety and efficacy of G. biloba continue to require verification through additional experimentation to guide medicinal use.Entities:
Year: 2022 PMID: 35265150 PMCID: PMC8901348 DOI: 10.1155/2022/8288818
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structures of flavonol, flavonoids (flavone, flavanone, isoflavone, flavan-3-ols, and biflavonoids), alkylphenols, alkylphenolic acids, carboxylic acids, and lignans.
Nutraceutical value of Ginkgo biloba [45].
| Main nutrition facts | Amount per 100 g |
|---|---|
| Sodium | 7 mg |
| Potassium | 510 mg |
| Calcium | 2 mg |
| Saturated fatty acids | 0.319 g |
| Calories | 182 Kcal (761.49 kj) |
| Calories from fat | 14.0616 Kcal (58.83 kj) |
| Cholesterol | 0 mg |
| Food energy | Amount per 100 g |
| Calories | 182 Kcal (761.49 kj) |
| Calories from protein | 14.9904 Kcal (62.82 kj) |
| Calories from carbohydrate | 153.032 Kcal (640.29 kj) |
| Calories from fat | 14.0616 Kcal (58.83 kj) |
| Fats and fatty acids | Amount per 100 g |
| Total fat | 4.75 ± 0.22 g |
| Polyunsaturated fat | 0.618 g |
| Monounsaturated fat | 0.619 g |
| Saturated fat | 0.319 g |
| Carbohydrates | Amount per 100 g |
| Carbohydrate by difference | 72.98 ± 0.20 g |
| Protein and amino acids | Amount per 100 g |
| Protein | 12.27 ± 0.24 g |
| Serine | 0.29 g |
| Proline | 0.34 g |
| Glycine | 0.23 g |
| Leucine | 0.31 g |
| Glutamic acid | 0.83 g |
| Histidine | 0.1 g |
| Valine | 0.28 g |
| Phenylalanine | 0.17 g |
| Arginine | 0.42 g |
| Cystine | 0.02 g |
| Alanine | 0.24 g |
| Methionine | 0.05 g |
| Aspartic acid | 0.54 g |
| Lysine | 0.2 g |
| Isoleucine | 0.2 g |
| Threonine | 0.26 g |
| Tryptophan | 0.07 g |
| Tyrosine | 0.06 g |
| Vitamins | Amount per 100 g |
| Vitamin C | 15 mg |
| Vitamin B1 | 0.22 mg |
| Vitamin B2 | 0.09 mg |
| Vitamin B3 | 0.16 mg |
| Vitamin B6 | 0.328 mg |
| Total folate | 54 |
| Vitamin B9 | 0 |
| Folate (dietary folate equivalents) | 54 |
| Food folate | 54 |
| Vitamin B12 | 0 |
| Vitamin A | 558 iu |
| Vitamin a (retinol activity equivalents) | 28 |
| Retinol | 0 |
| Vitamin D | 0 iu |
| Vitamin D | 0 |
| Minerals | Amount per 100 g |
| Manganese | 0.113 mg |
| Calcium | 2 mg |
| Copper | 0.274 mg |
| Iron | 1 mg |
| Zinc | 0.34 mg |
| Magnesium | 27 mg |
| Sodium | 7 mg |
| Phosphorus | 124 mg |
| Potassium | 510 mg |
| Sterols | Amount per 100 g |
| Cholesterol | 0 mg |
| Other nutrients | Amount per 100 g |
| Ash | 10.01 ± 0.06 g |
| Water | 55.2 g |
Major bioactive components of Ginkgo biloba.
| Class | Plant parts | Major chemical constituents | Bioactivity | References |
|---|---|---|---|---|
| Polyprenols | Leaf | Di-trans-poly-cis-octadecaprenol | Antibacterial properties and safety against the attack by A | [ |
| Flavonoids | Leaf | Quercetin (c), kaempferol (d), isorhamnetin (e), rutin, luteolin, delphidenon, myricetin | Antioxidation, anticancer, antibacterial, antiviral, anti-inflammatory, and neuroprotective effects | [ |
| Organic acids | Leaf | Benzoic acid derivatives (ginkgolic acid), N-containing acids | Inhibitory effects on xanthine oxidase (XOD) and antitumor properties | [ |
| Biflavonoids | Leaf | Sciadopitysin, ginkgetin, isoginkgetin, amentoflavone, bilobetin, 5′-methoxybilobetin | Antiadipogenesis and antiobesity properties and significant inhibitory effects on thrombin activity | [ |
| Terpenoids | Root | Triterpenes: sterols | Protective effects to cerebral hippocampal neurons from epilepsy, antioxidant, anti-inflammatory, antiplatelet, antilipidemic and antiapoptotic properties, enhanced memory and learning abilities, and reduced neuronal damage | [ |
| Leaf/root/bark | Sesquiterpene: bilobalide (b) | |||
| Leaf/root/bark | Diterpenes: ginkgolides | |||
| Leaf/root/bark | Diterpenes: ginkgolides A, B, C, and J (a) | |||
| Others | Leaf | Waxes, steroids, 2-hexenal, cardanols, sugars, catechins, proanthocyanidins, phenols, aliphatic acids, rhamnose | Antioxidant, anti-inflammatory, antidiabetic, antiapoptotic, antiradiation, antiviral, antitumor, hepatoprotective, and antiatherosclerosis pharmacological properties | [ |
Figure 2Chemical structures of Ginkgo biloba's key bioactive compounds.
Figure 3(a), (b) Therapeutic potential of Ginkgo biloba.
In vivo and in vitro studies on therapeutic effects of Ginkgo biloba.
| Field of study | Bioactive compounds | Subject | Dosage | Outcome | Mechanism of action | References |
|---|---|---|---|---|---|---|
| Treatment of respiratory diseases | Ginkgetin, biflavones | In vitro, A549 cells | 0.01, 0.1, 1, 10, and 40 mg/kg | ↓IL-4, ↓IL-5, ↓IL-6, ↓IL-8,↓IL-13, ↓TNF | Ginkgetin significantly reduced irregular expression of the Akt and p38 pathway, whereas biflavones reduced MUC5AC mRNA expression | [ |
| In vivo, an allergic mouse model | ||||||
| Ginkgolide B (GB) | In vitro, RAW 264.7 cell culture model | 10, 20 or 40 mg/kg | ↓LPS-induced IL-1 mRNA and protein levels, ↓IL-10 protein level, ↓exudation of plasma protein, ↓myeloperoxidase activities | GB and GM were shown to be a key component in the treatment of lipopolysaccharide-induced lung injury | [ | |
| Ginkgolides mixture (GM) | In vivo, mouse model | 19.1, 38.2 or 76.4 mg/kg | ||||
| Anticancer effects | GBE | In vivo, rats | 1 kg/2000 mL | ↑ING-3 gene expression, ↓FOXP1 gene expression, ↓AFP, ↓GPC-3, and ↓CEA | Treatment with | [ |
| GBEE | In vitro, C57BL/6J mice | 5, 10, 20, 40, 80 and 160 | ↓ | GBEE demonstrated the antitumor and antimetastatic actions due to the induction of the Wnt/ | [ | |
| GBE | In vitro, gastric carcinoma SGC7901 cells | 100, 200, 300, 400 mg/L | ↑G1 stage cell percentage, ↓S stage cell percentage, ↓mRNA and protein for the cyclin D1 and c-myc genes | GBE inhibited the proliferation of gastric carcinoma SGC7901 cells | [ | |
| GBE | In vitro, gastric cancer cells | GBE with 0.9% NaCl | Suppressed and inhibited expression of KSR1, p-KSR1, ERK1/2, and p-ERK1/2, ↓MDA, ↑GSH-Px, ↑SOD |
| [ | |
| Antidiabetic effect | Ginkgolide B | In vivo, rats | 5 mg−1 kg−1 day−1 | ↑SOD and eNOS operations, ↑H2S processing, ↓MDA, ↑mRNA expression of GPX1, ↑protein expressions of CBS and CGL, ↑mRNA, expression of GPX1 | Ginkgolide B reduced the progression of endothelial and vascular dysfunction in diabetic rats by increasing antioxidants and enhancing vascular control, and by increasing the expression of CBS and CSE, it prevented the development of vascular dysfunction | [ |
| Bilobalide | In vitro, 3 T3-L1 preadipocytes | 10, 20, and 50 | ↓Adipokine secretion, ↓NF-ĸB/JNK activation, ↑adiponectin | Bilobalide lowered the risk of developing type 2 diabetes by protecting against hypoxia-induced inflammation and other complications | [ | |
| Antiobesity effects | GBE | In vivo, rats | 500 mg/kg | ↓Nutrition/energy consumption, ↑Adipo R1 and ↓IL-10 gene expressions, ↑IR and Akt phosphorylation, ↓BW, ↓TNF-stages, ↓NF-ĸB p65 phosphorylation | Repeated therapy with GBE resulted in substantial visceral adiposity deficiency, improved insulin sensitivity, reduced dyslipidemia, and activated the insulin signaling cascade. | [ |
| Ginkgolide B | In vivo, C57BL/6 mice | 0.1 g/100 g | ↑mRNA expression of PXR | Ginkgolide B therapy reduced body weight gain and increased hypertriglyceridemia | [ | |
| Ginkgolide C | In vitro, HepG2 hepatocytes | 3–100 | ↑Lipolysis, ↓lipid aggregation, ↑mRNA expression of ATL | Ginkgolide C decreased oleic acid-induced lipid aggregation | [ | |
| Isoginkgetin, bilobetin, ginkgetin, and sciadopitysin | In vitro, pancreatic lipase | 2.90 | Inhibited pancreatic lipase | Biflavones in | [ | |
| Antilipidemic effects | GBE | In vivo, rabbits (p.o for 6 weeks) | 10 mg˗1 kg−1 day | ↓TC, ↓TG, ↑HDL-C, ↓MDA, ↑GSH |
| [ |
| Treatment of cardiovascular diseases |
| In vivo high-fat diet (HFD) mice (p.o. for 4 weeks) | 300 mg/kg/day | ↓High-fat diet mice's epididymal adipose tissue weight and adipocyte size, ↓high-density lipoprotein | Seeds of | [ |
| Detoxified | In vivo obese C57BL/6J mice | 0.67 mg/kg ginkgolic acid, and 701.3 mg/kg gingko flavonoids | ↓Liver and body fat weights, ↓serum and hepatic amounts of triglyceride, ↓low-density lipoprotein cholesterol, ↓total cholesterol, ↓leptin, ↑PPAR | Detoxified | [ | |
| Antimicrobial effects | Ginkgolic acids | Two bacteria and four fungi | 0.11 g/kg |
| Ginkgolic acids had a wide antimicrobial repertoire against bacteria such as | [ |
| Antioxidant effects | Ginkgolide B | In vitro, human neuroblastoma SH-SY5Y cells | 0–100 | ↓ROS/RNS, ↑mitochondrial APE1 level, ↑OXPHOS complexes I and IV activity | Ginkgolide B restored the neuroprotective function of apurinic/apyrimidinic endonuclease 1 and mitochondrial oxidative phosphorylation against A25-35-induced neurotoxicity | [ |
| GBE | In vivo C57BL/6J male mice | 20, 40, 80, or 100 mg/kg | ↑Glutathione, ↑superoxide dismutase, ↓MDA, ↓NO, ↑phosphatase PP2A | GBE or similar drugs may be used as a long-term therapeutic alternative in elderly patients with ischemic brain injuries | [ | |
| GBE | In vivo, cisplatin-administrated rats | 100 mg/kg | ↓NO, ↓GSH, did not affect the decreased MDA levels | GBE reduced cisplatin's oxidative stress-related neurological side effects | [ | |
| GBE | In vivo, rats | Dissolved in 0.1% methyl alcohol | ↓Intracellular ROS, ↓GSK3 | GBE demonstrated antioxidative activities by affecting the modulation of GSK3 to suppress zinc-induced tau phosphorylation at Ser262 | [ | |
| GBE | In vivo, aged female rats | 100 mg mL−1 | ↓8-OHdG, ↓MDA, ↑BDNF levels, ↓locomotor activity, ↓anxiety levels | GBE supplementation increased cognitive functions by reducing oxidative damage and increasing BDNF levels | [ | |
|
| GBE | In vivo, Sprague Dawley rats | 40 mg/kg/day | ↑TSSA, ↑NSSA, ↑GRD, ↑GST, ↓XO | GBE has strong antioxidant properties and is likely to be a valuable medication for gamma-irradiation safety and/or as an antioxidant against oxidative stress | [ |
| GBE | In vitro, normal human keratinocytes (NHKs) | 5 kg of fresh leaves dissolved in 0.1–1% concentrated fresh medium | ↓VEGF, ↓CXCL8/IL-8 levels | GBE, alone or in combination with EGCG, led to mild inflammation processes in angiogenesis-related skin diseases | [ | |
| GBE | In vivo, Fisher rats | 200, 100, and 50 mg/kg | ↓Wound surface area, ↓4-hydroxy-2-nonenal-stained cells, ↓8-hydroxy-2′ deoxyguanosine-stained cells | Extract of | [ | |
| Antiplatelet activity | Ginkgolide A | In vitro, human umbilical vein endothelial cells (HUVECs) | 10, 15 and 20 | IL-4, IL-6, IL-13, signal transducer, and activator of transcription-3 (STAT3) phosphorylation were substantially inhibited | Ginkgolide a demonstrated STAT3-mediated inhibition of inflammatory response in high-glucose-stimulated human umbilical vein endothelial cells | [ |
| Ginkgolide B | In vitro, freshly human platelets | 0.6 mg/ml | ↓PF4 and CD40L expression, ↓phosphorylation of Syk and p38MAP, ↓Ca+2efflux | Ginkgolide B prevented platelet release by inhibiting the phosphorylation of Syk and p38 MAPK in thrombin-stimulated platelets | [ | |
|
| In vitro, Sprague-Dawley rats | 27.69% bilobalide, 37.15% ginkgolide A, 22.04% ginkgolide B, and 11.66% ginkgolide C | The AUC and CMax of GC are smaller than those of the other ginkgolides, and it is methylated in vivo much faster than the other GBE constituents | Oral | [ | |
| Bilobalide | In vitro, 3T3-L1 adipocytes | 10, 20 and 50 | ↑HIF-1 | Bilobalide lowered hypoxia-induced oxidative stress, inflammation, and mitochondrial dysfunction in 3T3-L1 adipocytes | [ | |
| Antihypertensive effects | GBE | In vivo, rats | 100 mg−1 kg−1 day−1 | ↑GSH, ↓nitrite levels, ↑protein expressions of iNOS, TNF- | The standardized extract of | [ |
| Neuroprotective effects | GBE | In vivo, APP/PS1 transgenic mouse model of AD | 50 mg/kg | ↓Insoluble amyloid beta (a | GBE protected the APP/PS1 mouse from damage by regulating inflammation in the brain | [ |
| GBE and donepezil | In vivo, aged rats | GBE (100 mg/kg/day), donepezil (1.5 mg/kg/day) | ↑Basal ACh levels, ↓AChE, ↓HACU ↓ extracellular choline release, ↑ChAT activity | GBE and donepezil combination demonstrated neuroprotective properties by lowering choline levels | [ | |
| Antiaging effect | Flavonoids, lactones, kaempferol 3-O- | In vitro, human dermal fibroblasts (HDFs) | n.m. | Improved skin condition and antiaging effect |
| [ |
| Immunomodulatory effects |
| In vivo, rainbow trout fish | In non-diazinon fish, 1 and 2 g GB/kg diet for 60 days. In diazinon-exposed fish, 0.5 and 4 g GB/kg diet was fed | Enhanced the immunity at optimum dietary levels (1-2 g/kg diet) but showed immunosuppressive effects at high dietary levels (4 g/kg diet) |
| [ |
| Anti-inflammatory effect |
| In vivo, 28-day-old BALB/ | 10 mg/kg of body weight for low dosage and 40 mg/kg of body weight for high dosage form | Showed anti-inflammatory effect in airway inflammation | Ginkgetin reduced the expression of mRNA MUC5AC and regulates pathways p38 and Akt of the A549 cell model stimulating HNE | [ |
| Ethanol extract of | In vitro, RAW264.7 murine macrophage cell | Different extractive fractions at 10 | Effectively inhibited the generation of proinflammatory cytokines and mediators, making them valuable for the treatment of inflammatory disease | Bilobetin and isoginkgetin can dramatically downregulate the levels of NO, TNF- | [ | |
| Hepatoprotective effect |
| In vivo, male SD rats | For 7 days, 60, 120, and 180 mg/kg daily dose before MTX treatment); silymarin (followed by MTX treatment) | Showed antioxidant and anti-inflammatory effects in methotrexate (MTX) induce marked hepatic injury |
| [ |
| Anti-depressant effect | Diterpene ginkgolides (DGs) | In vivo, mice | DG (12.18 mg/kg) and venlafaxine (16 mg/kg) for 14 days | Exhibited antidepressant-like, but not anxiolytic-like, effects | DG reduced depressive symptoms and produced neuroprotective effects on the prefrontal cortex by changing differential metabolites primarily involved in amino acid, energy, and lipid metabolism | [ |
Clinical studies on therapeutic effects of Ginkgo biloba.
| Field of study | Bioactive compound | Subject | Dosage | Outcome | Mechanism of action | Reference |
|---|---|---|---|---|---|---|
| Anticancer effects | GBE (extract of | Human patients | 240 mg EGb (QD) and 400 mg sorafenib (BID) | The combined toxicity profile of GBE and sorafenib proved to be close to that of GBE and sorafenib monotherapy. | GBE in combination with sorafenib increased safety and tolerance in patients with advanced HCC | [ |
| Antidementia effects | GBE | Human patients | 240 mg/day | ↓Loss in memory, function, behavior, and global shift | GBE increased cognitive function, ADLs, and CGIC and decreased neuropsychiatric symptoms with statistical superiority in patients with cognitive dysfunction and dementia | [ |
| EGb761 | Human patients | n.m. | ↑Cognition and ↓neuropsychiatric symptoms |
| [ | |
| EGb 761 | Human patients | 120 mg/day | ↑Cognitive function | In comparison to the placebo group, those who were given EGb 761 saw a substantial increase in cognitive performance. | [ | |
| EGb 761 | Human patients | 240 mg/day | ↑Cognitive function ADLs | In contrast to the placebo group, EGb 761 improved cognitive performance markedly. | [ | |
| EGb 761 | Human patients | 120 mg/day; 240 mg/day | ↑Cognition and ↓neuropsychiatric symptoms | In a subset of individuals with neuropsychiatric symptoms, the EGb 761 group outperformed the placebo group. | [ | |
| EGb 761 | Human patients | 240 mg/day | ↑Cognition and ↓neuropsychiatric symptoms | In opposed to the placebo group, the EGb 761 group showed considerable improvement in all clinical parameters, including neuropsychiatric symptoms. | [ | |
| GBE (extract of gingko biloba) | 189 patients | EGb (240 mg/day) or donepezil (5 or 10 mg/day) | EGb 761, which is used to treat dementia in people with Alzheimer's disease, has similar effects on cognitive symptoms as donepezil, and it is less dangerous than donepezil. | n.m. | [ | |
| GBE (extract of gingko biloba) | 400 patients | 240 mg/day | EGb 761 was found to be better than a placebo for people with dementia who had neuropsychiatric symptoms | EGb 761 is a polyvalent radical scavenger that helps mitochondria work better. It decreases blood viscosity, improves microperfusion, stops the formation of synaptotoxic A-oligomer, and reduces the toxicity of amyloid. | [ | |
| Antidiabetic effects | GBE | Human, T2DM patients | 120 mg/day | ↓HbA1c, ↓FBG, ↓plasma insulin, ↓BMI, ↓waist circumference, ↓VAI | GBE primarily improved the glycemic control through the suppression of release of glucose from the liver | [ |
| Treatment of tardive dyskinesia | GBE (extract of gingko biloba) | 3 human randomized controlled trial (RCT) | 240 mg/day, 12 weeks duration | Reduced the severity of TD and clinical symptoms. | GBE scavenges free radicals and inhibited the formation of free radicals that reduce oxidative stress, enhance BDNF levels, and decrease the chance of neurotoxicity | [ |
| Treatment of generalized anxiety disorder (GAD) | GBE | Patients with GAD (25–30 patients per group) | 240 mg and 480 mg placebo for four weeks | Improve cognitive functions and reduce anxiety under pathological conditions | Flavonoids in GBE demonstrated powerful antioxidant qualities which helped to reduce anxiety-like disorders | [ |
| Antilipidemic effects |
| Human patients | A variety of doses | ↓TC, ↑HDL-C, ↓LDL-C, ↓TG |
| [ |
| Antidepressant effect |
| 136 depressed elderly patients | 19.2 mg per time and 3 times a day | Improved depressive symptoms and decreased serum S100B expression. | GBE restored neurologic function and shows the antidepressant-like effect via modulation of serotonergic and dopaminergic neurotransmission | [ |
| Treatment of vitiligo vulgaris |
| 12 participants between 12 and 35 years old | 60 mg of standardized |
| Having anti-inflammatory, immunomodulatory, and antioxidant properties, | [ |
| Treatment of ADHD |
| 50 patients | Ginko T.D.™ at a dose of 80–120 mg/day for 6 weeks |
| n.m. | [ |